drugset / Trial / NCT06055075
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
Timeline
- Start
- 2023-12-08
- Primary completion
- 2025-07-08
- Completion
- 2025-07-08
Outcome
Outcome not reported
Stopped: “The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Forimtamig | Monoclonal antibody | — | Subcutaneous |